New drug combo aims to fight Hard-to-Treat breast cancer recurrence

NCT ID NCT06008275

Recruiting now Disease control Sponsor: Baylor Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether combining two oral drugs, neratinib and ruxolitinib, is safe and can shrink tumors in people with metastatic triple-negative breast cancer that has come back on the chest wall after chemotherapy. About 20 women will take the drugs daily, and doctors will measure how many respond. The goal is to find a new option for this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: neratinib and ruxolitinib (oral tablets)
What this could lead to: If it works, this could point toward a new treatment option for people with metastatic triple-negative breast cancer that has returned on the chest wall.
What could go wrong: This is a very early, small trial (20 people) focused on safety and dosing. The combination may not shrink tumors or could cause side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA

Contacts and locations

Locations

Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
RECRUITING

Dallas, Texas, 75246, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.